title: The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
authors.affiliation: Baker Botts LLP, NY, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Ritter
authors.forename: Jennifer
authors.initials: J
authors.lastname: Tempesta
authors.forename: Paul
authors.initials: P
authors.lastname: Ragusa
mesh_terms: D016363:Antitrust Laws; D000069059:Atorvastatin / Q000191:economics; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000191:economics*; D064098:Esomeprazole / Q000191:economics; D000077213:Lamotrigine; D007880:Legislation, Drug; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D035521:Supreme Court Decisions; D014227:Triazines / Q000191:economics; D014481:United States; D014485:United States Federal Trade Commission / Q000331:legislation & jurisprudence
chemical_list: D016568:Drugs, Generic; D014227:Triazines; D000069059:Atorvastatin; D064098:Esomeprazole; D000077213:Lamotrigine